Two new AGA updates reshape how clinicians test for, treat, and prevent recurrent C difficile, including tailored guidance for patients with IBD.

Drs Alexander and Urey walk through stabilizers vs silencers, pivotal trial data, and practical first line choices to help you select the right ATTR CM therapy for each patient.

When fatty liver appears incidentally on imaging, "just lose weight" isn't enough. Dr Brandman explains how to use FIB-4, FibroScan, and ELF to triage who needs referral and who doesn't.

Dr Maurie Markman discusses why modifying cancer diets without RCT data poses major risks, highlighting a trial halted due to a 10% spike in serious infections.

With a 34-state Cyclospora outbreak driving GI visits, Dr Levy breaks down diagnosis, testing pitfalls, and treatment clinicians need to know.

From missed red flags to insurance denials, the barriers to ATTR-CM care are multi-level. Drs Alexander and Pino-Moreno break down what’s failing and how to fix it.

Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Dr Yash Varma, a chief cardiology fellow, asks Dr Ileana Piña for her insights on when a patient with heart failure should be referred for advanced therapies.

Chief Cardiology fellow Yash Varma asks HF expert Ileana Piña for tips on when patients are stable to discharge on guideline-directed medical therapy and if it’s ever ok to de-escalate.